LDL receptor genetics - Lipid · LDL receptor gene • Structure • Mutations related to FH •...

34
LDL receptor genetics Nathan Stitziel, MD, PhD Assistant Professor of Medicine and Genetics Director, Center for Cardiovascular Genetics Assistant Director, McDonnell Genome Institute

Transcript of LDL receptor genetics - Lipid · LDL receptor gene • Structure • Mutations related to FH •...

  • LDL receptor genetics

    Nathan Stitziel, MD, PhDAssistant Professor of Medicine and GeneticsDirector, Center for Cardiovascular Genetics

    Assistant Director, McDonnell Genome Institute

  • DisclosuresNone

  • “Breaking” a gene: a review of terminology

    LDL receptor gene• Structure• Mutations related to FH• Finding mutations related to FH

    Beyond LDLR: Other genetic causes of hypercholesterolemia

    Putting it all together: genetic testing in FH

  • DNA(Gene)

    What is a Gene? A review of terminologyExons

    Introns

    pre-mRNA

    Transcription

    Splicing

    mRNA

    mRNA

    Translation

    Met

    A U G C G G U G G U A G

    Promotor

    Arg TrpPolypeptide STOP

    Post-translational modifications

    Active protein

  • Breaking a gene: A review of terminologyDNA

    (Gene)mRNA

    Met

    A U G U G G C G G U A G

    Trp ArgPolypeptide STOP

    Missense

    Met

    A U G U G C C G G U A G

    Cys Arg STOP

    Nonsense

    Met

    A U G U G A C G G U A G

    STOP

    Splice-site

    Aberrant Splicing

    Single nucleotide changes in DNA

    pre-mRNA

    mRNA

    Most missense changes tolerated

    Most nonsense changes nottolerated

    Most splice-site changes nottolerated

  • Breaking a gene: A review of terminologyDNA

    (Gene)mRNA

    Met

    A U G U G G C G G U A G

    Trp ArgPolypeptide STOP

    Single nucleotide changesMissenseNonsenseSplice-siteStartlossStoploss

    Small insertions or deletions in DNA

    Met

    A U G C U G G C G G U A G

    Leu Ala

    Frameshift

    Val Met

    A U G C G G U A G

    Arg

    Inframe

    STOP

    pre-mRNA

    mRNA

    Most frameshift changes nottolerated

    Some inframe changes tolerated

  • Breaking a gene: A review of terminologyDNA

    (Gene)mRNA

    Met

    A U G U G G C G G U A G

    Trp ArgPolypeptide STOP

    Single nucleotide changesMissenseNonsenseSplice-siteStartlossStoploss

    Small insertions or deletionsFrameshiftInframe

    Large structural variants in DNA

    pre-mRNA

    mRNA

    Deletion

    DuplicationMost large SVs not tolerated

  • Breaking a gene: A review of terminologyDNA

    (Gene)mRNA

    Met

    A U G U G G C G G U A G

    Trp ArgPolypeptide STOP

    Single nucleotide changesMissenseNonsenseSplice-siteStartlossStoploss

    Small insertions or deletionsFrameshiftInframe

    Large structural variants (SVs)DeletionDuplicationTranslocation/inversion

    pre-mRNA

    mRNA

  • Breaking a gene: A review of terminologySingle nucleotide changes

    MissenseNonsenseSplice-siteStartlossStoploss

    Small insertions or deletionsFrameshiftInframe

    Large structural variants (SVs)DeletionDuplicationTranslocation/inversion

    Heterozygous

    Homozygous

    Compoundheterozygous

    Doubleheterozygous

  • Soutar AK and Naoumova RP. Nat Clin Pract Cardiovasc Med 2007

  • Soutar AK and Naoumova RP. Nat Clin Pract Cardiovasc Med 2007

  • Soutar AK and Naoumova RP. Nat Clin Pract Cardiovasc Med 2007

  • Soutar AK and Naoumova RP. Nat Clin Pract Cardiovasc Med 2007

  • LDLR mutations causing FH

    Over 1,000 LDLR mutations identified for FH

    Receptor negativeNo residual LDLR function (

  • LDLR mutation type affects LDL level

    Bertolini et al ATVB 1999

    N=32 HoFH

  • LDLR mutation affects drug response

    HMG-CoA

    HMG-CoA Reductase

    Mevalonate

    Cholesterol

    Statins

    LDL receptors

    Efficacy in HoFH varies substantially:

    LDLR receptor defective HoFH patients respond much better than LDLR receptor negative patients

  • LDLR mutation affects drug response

    LDLR receptor negative HoFH patients have little

    response to PCSK9 inhibition

    Mullard Nat Rev Drug Discovery 2012

  • FH: a co-dominant condition

    Adapted from Soutar AK and Naoumova RP. Nat Clin Pract Cardiovasc Med 2007

    LDL=413 mg/dL

    LDL=347 mg/dL

    LDL=154 mg/dL

    LDL=301 mg/dL

    LDL=278 mg/dLLDL=204 mg/dL

    LDL=695 mg/dL

    When possible, genetic testing

    should be pursued in

    family members with

    the most extreme

    phenotype

  • Beyond LDLR: other FH genes• Autosomal-dominant (or co-dominant)

    hypercholesterolemia caused by:• LDLR• APOB• PCSK9

    • Autosomal-recessive hypercholesterolemia caused by:• LDLRAP1

    • Other notable recessive genes:• ABCG5, ABCG8, LIPA

  • Finding mutations causing FHHistorical “Gold standard”: Sanger sequencing

    Identifies all mutated basesIdentifies small insertions and deletions

    Homozygousreference Heterozygous Homozygous

    Heterozygous for frameshift

  • Finding mutations causing FHHistorical “Gold standard”: Sanger sequencing

    Identifies all mutated basesIdentifies small insertions and deletionsCostly and labor-intensive

    Additional screening techniques previously used:High-resolution Melting Analysis (HRM)Single-Strand Conformation Polymorphism (SSCP)Denaturing Gradent Gel Electrophoresis (DDGE)and others

    Goal of these techniques is to detect a region of the gene with possible sequence variant to focus subsequent Sanger sequencing

  • Finding mutations causing FHHistorical “Gold standard”: Sanger sequencing

    Identifies all mutated basesIdentifies small insertions and deletionsCostly and labor-intensive

    Multiplex Ligation-dependent Probe Amplification (MLPA) used historically and typically today to detect large deletions and duplications

    Next-generation sequencing becoming standard for many sequencing-based diagnostic tests

  • How common are FH mutations?

    What is the impact of FH?

  • • 10,094 children, screened in early childhood (~1 year age)

    • Screened all children for 48 most common FH mutations

    • Full genetic evaluation in children with total cholesterol >95%

    • Mutation carrier prevalence 1:273

    Wald et al, NEJM 2016

    Prevalence of FH: ~1:250

  • Clinical impact of FH mutations?

    OR for CAD

    OR of CAD adjusted for LDL

    LDL > 190 mg/dLwithout FH mutation

    6 1.6

    LDL > 190 mg/dLwith FH mutation 22 4.2

    Diagnostic Yield and Clinical Utility of Sequencing Familial

    Hypercholesterolemia Genes in Patients with Severe

    Hypercholesterolemia

    Khera et al, JACC 2016

    OR for CAD

    LDL > 190 mg/dLwithout FH mutation

    6

    LDL > 190 mg/dLwith FH mutation 22

  • Beyond FH genes: other causes of hypercholesterolemia

    41 families with monogenic dyslipidemia

    13 with hypercholesterolemia

    No mutations in LDLR, APOB, PCSK9 found clinically

    3 families (of 13) harbored causal FH mutations: 23%

    Stitziel et al, Circ Cardiovasc Genet 2015

  • Beyond FH genes: other causes of hypercholesterolemia

    Exome sequencing in 125 unrelated FH patients (clinical testing negative)

    20% (25/125) had FH mutation previously undiscovered

    Futema et al, J Med Genet 2014

  • Beyond FH genes: other causes of hypercholesterolemia

    Population lipid values

    Three possibilities:

    1. Single gene with large effect(monogenic i.e. LDLR)

    2. Multiple genes of small effect (polygenic)

    3. Environment

    How does one get to the 1% tail?

  • Beyond FH genes: other causes of hypercholesterolemia

    Multiple genes of small effect (polygenic)

    Common genetic variation explains ~20% of population heritability for lipid levels.

    Can common variation explain some individual’s extreme LDL value?

    nn SNPSNPSNPLDL *...** 22110 ββββ ++++=

    Population polygenic LDL score

    Likely monogenic etiology

    Likely polygenic etiology

  • Beyond FH genes: other causes of hypercholesterolemia

    Multiple genes of small effect (polygenic)

    Approximately 15-20% of individuals with severe hypercholesterolemia likely have a polygenic etiology

  • Putting it all together: clinical genetic testing in FHClinical genetic testing for FH is available from several molecular diagnostic laboratories

    Most labs perform Sanger or next-generation sequencing of LDLR, APOB, PCSK9, and/or LDLRAP1. Polygenic scores not available clinically.

    Some offer single gene testing (LDLR) with reflex to deletion/duplication and/or other FH genes

    Mostly covered by insurance

  • Putting it all together: a practical approach to clinical genetic testing in FH

    1) If previous FH genetic evaluation negative and done using “older” technology, can consider repeat testing

    2) Some individuals have more than 1 mutation.

  • Putting it all together: a practical approach to clinical genetic testing in FH

    1) If previous FH genetic evaluation negative and done using “older” technology, can consider repeat testing

    2) Some individuals have more than 1 mutation. Full FH panel in the most affected individual offers the most comprehensive genetic evaluation.

    3) FH is common (~1:200-250) and has significant impact.

    4) FH genetic testing can identify causal mutation in ~80% of individuals. Other causes include polygenic inheritance, environment, and unidentified monogenic causes.

    LDL receptor genetics��Nathan Stitziel, MD, PhD��Assistant Professor of Medicine and Genetics�Director, Center for Cardiovascular Genetics�Assistant Director, McDonnell Genome Institute�DisclosuresSlide Number 3What is a Gene? A review of terminologyBreaking a gene: A review of terminologyBreaking a gene: A review of terminologyBreaking a gene: A review of terminologyBreaking a gene: A review of terminologyBreaking a gene: A review of terminologySlide Number 10Slide Number 11Slide Number 12Slide Number 13LDLR mutations causing FHLDLR mutation type affects LDL levelLDLR mutation affects drug responseLDLR mutation affects drug responseFH: a co-dominant conditionBeyond LDLR: other FH genesFinding mutations causing FHFinding mutations causing FHFinding mutations causing FHHow common are FH mutations?�� What is the impact of FH?Prevalence of FH: ~1:250Clinical impact of FH mutations?Beyond FH genes: other causes of hypercholesterolemiaBeyond FH genes: other causes of hypercholesterolemiaBeyond FH genes: other causes of hypercholesterolemiaBeyond FH genes: other causes of hypercholesterolemiaBeyond FH genes: other causes of hypercholesterolemiaPutting it all together: clinical genetic testing in FHPutting it all together: a practical approach to clinical genetic testing in FHSlide Number 33Putting it all together: a practical approach to clinical genetic testing in FH